semaglutide for type 1 semaglutide seems to have the ability to reduce the glucose variability - Semaglutidein adults withtype 1diabetes and obesity semaglutide in new-onset type 1 diabetes Exploring the Potential of Semaglutide for Type 1 Diabetes Management

Semaglutide type 1diabetes weight loss The landscape of diabetes management is continually evolving, and recent research has shed light on the potential benefits of semaglutide for individuals with type 1 diabetes. While traditionally prescribed for type 2 diabetes and weight management, emerging studies suggest that semaglutide may offer significant advantages for those with type 1 diabetes, particularly concerning glycemic control, weight management, and insulin dose requirements. This exploration delves into the current understanding of semaglutide's role in type 1 diabetes treatment, supported by clinical trial data and expert insights.作者：VN Shah·2025·被引用次数：36—The efficacy and safety of semaglutide in adults with type 1 diabetes are not established.

Semaglutide: A Novel Approach to Glycemic Control

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, functions by mimicking the effects of naturally occurring GLP-1 hormones. These hormones play a crucial role in regulating blood sugar levels by stimulating insulin secretion and suppressing glucagon release.2024年8月28日—A new clinical trial investigating the use ofsemaglutide for type 1 diabetes(T1D) has launched in Sydney and is actively recruiting. For individuals with type 1 diabetes, where the pancreas does not produce enough insulin, the precise mechanisms by which semaglutide exerts its benefits are still under investigation. However, multiple studies indicate that semaglutide has demonstrably improved glycemic control.作者：MR Pasqua·2025·被引用次数：47—In this trial,semaglutide improved glycemic control, with lower insulin requirements, in adults with T1D when used with AID. Semaglutide also ... The SMILE trial, for instance, is testing whether semaglutide can assist children and young people with type 1 diabetes in managing their blood sugar levels alongside insulin therapy. Furthermore, research indicates that semaglutide and tirzepatide have improved glycemic control, with a mean reduction in HbA1c ranging from –0.20% to –0.60%. Similarly, a double-blind clinical trial showed that weekly semaglutide improves blood sugar and weight in adults with Type 1 diabetes. Another study highlighted that semaglutide treatment has been shown to improve glycemia, is associated with weight loss without an increased incidence of hypoglycemia.The goal of this clinical trial is to investigate the efficacy ofsemaglutide on body weight, insulin dose requirements and improvements in glucose controland ...

Addressing Weight Management and Insulin Needs

A significant finding across several studies is that semaglutide use in type 1 diabetes is often associated with weight loss.2025年6月23日—Semaglutide improved time spent in glycemic range, time below rateand reduced body weight with low rates of hypoglycemia compared with placebo in patients ... This is particularly relevant for individuals with type 1 diabetes and obesity.Ozempic and Other GLP-1 Drugs for Type 1 Diabetes: Benefits and Risks One clinical trial reported that semaglutide treatment was associated with weight loss without an increased incidence of hypoglycemia. The efficacy of semaglutide in lowering body weight and BMI, and improving glycemic control in patients who are overweight and/or obese with T1D, has been concluded from research.NCT05822609 | Trial of Semaglutide for Diabetic Kidney ... For example, a trial using Semaglutide 0.5mg in people living with T1D and excess weight might result in a significant weight loss of approximately 11%, associated with a reduction in other parameters.Semaglutide in Adults with Type 1 Diabetes and Obesity

Beyond weight, semaglutide also appears to influence insulin requirements. Studies suggest that semaglutide improved glycemic control, with lower insulin requirements, when used with automated insulin delivery systems.2025年6月23日—Semaglutide improved time spent in glycemic range, time below rateand reduced body weight with low rates of hypoglycemia compared with placebo in patients ... Research has indicated that semaglutide produced rapid, sustained, and primarily bolus-driven insulin dose reductions, with early effects being largely independent of weight loss in adults with T1D and obesity. In some cases, semaglutide has been associated with less insulin need in early type 1 diabetes. For instance, treatment with semaglutide in newly diagnosed Type 1 diabetes patients may drastically reduce or even eliminate their need for insulinOzempic May Reduce Insulin Needs in People With Type 1 ....

Safety and Considerations

While promising, it's crucial to acknowledge that the efficacy and safety of semaglutide in adults with type 1 diabetes are not yet fully established, and it is generally considered an off-label use of semaglutide and tirzepatide shows promise in type 1 diabetes. A primary concern when using GLP-1 receptor agonists in type 1 diabetes is the potential risk of hypoglycemia and diabetic ketoacidosis (DKA). Therefore, meticulous monitoring of blood glucose levels and close collaboration with a healthcare provider are paramount. Certain medications might not be suitable for some people, which might be because of medical conditions or other reasonsSubcutaneous weekly semaglutide with automated insulin .... Generally, Wegovy is recommended by NICE guidelines for adults who have a BMI of 30kg/m2 and over, and at least one weight-related health condition.Type 1 and Semaglutide : r/Type1Diabetes

The impact of semaglutide also extends to potential cardiovascular benefits. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI. Furthermore, research is investigating the effects of semaglutide on kidney oxygenation and function in type 1 diabetes.

Ongoing Research and Future Directions

The medical community is actively exploring the role of semaglutide in type 1 diabetes. Numerous clinical trials, such as NCT06909006 and NCT05822609, are underway to further investigate the semaglutide on body weight, insulin dose requirements and improvements in glucose control and its effects on kidney function. Initial findings from randomized clinical trials are encouraging, demonstrating that semaglutide use in type 1 diabetes is associated with improved glucose management, weight loss, and lower insulin requirements.Impact of adding semaglutide in a person with type 1 ... The ADJUST-T1D trial, for example, compared semaglutide to placebo, showing a significant disparity in semaglutide's favorEfficacy of Semaglutide in Overweight and Obese Patients .... Evidence suggests that semaglutide (Ozempic) or tirzepatide (Mounjaro) have the potential to lower A1c, increase time-in-range, and reduce other health concerns.

Individual experiences shared online also reflect a positive impact, with users reporting significant weight loss, decreased appetite, and reduced insulin needs作者：E Harris·2023·被引用次数：3—Semaglutide, a glucagon-like peptide 1 receptor agonist, soon after being diagnosed withtype 1diabetes didn't need to take insulin with meals after 3 months .... While semaglutide is *a medication typically prescribed to Type 2 diabetes patients*, its growing study in type 1 diabetes suggests a shift in treatment paradigms. As more data becomes available from semaglutide type 1 diabetes trials, a clearer picture will emerge regarding its long-term efficacy and safety for this patient population.

In conclusion, semaglutide is showing promising potential as an adjunct therapy for individuals with type 1 diabetes, offering benefits in glycemic control, weight management, and potentially reducing insulin needs. However, its use should be carefully considered under the guidance of a healthcare professional, with ongoing monitoring and research playing a vital role in defining its established place in type 1 diabetes management.